title: [Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders].
abstract: BACKGROUND
  Hydroxyurea (HU) is usually a well-tolerated antineoplastic agent, which is commonly used in the treatment of myeloproliferative disorders. Dermatological abnormalities are often seen in patients receiving long-term HU therapy. Leg ulcers have been reported occasionally.
  
  
  METHODS
  We carried out a prospective and descriptive study of patients who developed leg ulcers while receiving HU therapy.
  
  
  RESULTS
  Between 1.1.1997 and 1.2.1998, chronic cutaneous leg ulcers were found in five out of a total of 28 patients treated with HU. The average age was 76 years (64-87 years). Two patients had chronic myelogenous leukaemia in a non-accelerated phase, two polycytaemia vera, and one essential thrombocytosis. The average duration of HU therapy was 30 months (10-55 months) before ulcerations appeared. These were typically located on the malleolar and/or perimalleolar area, and were very painful. HU therapy was discontinued and replaced by busulphan or anagrelide. Within 1.5-11 months of discontinuation of the treatment, the wounds had healed or improved.
  
  
  CONCLUSIONS
  We found a surprisingly high number of cutaneous leg ulcers in patients on HU therapy for chronic myeloproliferative disorders. We believe this disabling complication should be given greater attention and recommend that it is included in the description of the side effects of the drug.
authors.affiliation: Viborg-Kjellerup Sygehus, medicinsk afdeling.
authors.forename: L H
authors.initials: LH
authors.lastname: Olesen
authors.forename: B B
authors.initials: BB
authors.lastname: Pedersen
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000009:adverse effects*; D007871:Leg Ulcer / Q000139:chemically induced* / Q000473:pathology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000188:drug therapy*; D011087:Polycythemia Vera / Q000188:drug therapy; D011446:Prospective Studies; D012883:Skin Ulcer / Q000139:chemically induced* / Q000473:pathology; D013922:Thrombocytosis / Q000188:drug therapy; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D006918:Hydroxyurea
vernacular_title: Hydroxyurea-inducerede underekstremitetsulcera hos patienter med kroniske myeloproliferative tilstande.